Hosted on MSN
Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck’s Keytruda
Pfizer (PFE) and Astellas Pharma (ALPMY) announced on Wednesday that their antibody drug conjugate Padcev, with Merck’s (MRK) anti-PD-1 therapy Keytruda, succeeded in a Phase 3 pivotal trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback